Loading…
Employees: 532
Size Myung in Pharm (317450.KS) is a South Korea Health Care company (Pharmaceuticals: Other) with a market value of $455M, the 356th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩42,350 on 6 Nov 2026.
Performance Over six months the shares fell 24.1%, against -21.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 6.6% over the last twelve months (peer median -3.3%); the operating margin is 34.8% (peer median 10.8%).
Valuation It trades at 2.1× enterprise value to sales against a peer median of 2.7× (8th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.1 points above its cost of capital (5.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩297B | ₩287B | ₩269B | ₩242B | ₩226B |
| Revenue growth | — | +7% | +11% | +7% | — |
| Gross profit | n/a | ₩179B | ₩173B | ₩157B | ₩147B |
| EBITDA | n/a | ₩103B | ₩105B | ₩95.1B | ₩87.2B |
| Net income | ₩91.5B | ₩81.4B | ₩68.7B | ₩74.5B | ₩57.4B |
| Free cash flow | n/a | ₩51.5B | ₩72.8B | ₩71.4B | ₩57.6B |
| Capital expenditure | n/a | ₩34.8B | ₩10.2B | ₩4.65B | ₩3.40B |
| Total debt | n/a | ₩1.39B | ₩2.70B | ₩3.89B | ₩4.95B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 317450.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.3% | -9.1% | 5th highest of 21 |
| 6-month return | -24.1% | -21.2% | 7th lowest of 21 |
| Distance from 52-week high | -54.3% | -38.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | +6.6% | -3.3% | 5th highest of 19 |
| Operating margin | 34.8% | 10.8% | highest of 20 |
| EV / Sales | 2.1× | 2.7× | 8th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -14.7% | 2.4% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +8.9% | +4.8% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -23.6 pp | -0.9 pp | least demanding of 14 |
| ROIC minus cost of capital | +4.1 pp | -0.2 pp | 7th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | 2.1× | -14.7% | +8.9% |
| Tibet Aim Pharm 002826.SZ | China | $427M | -23% | +13% | 14% | 3.1× | 1.3% | +1.0% |
| Boiron BOI.PA | France | $391M | -31% | -2% | 5% | 0.7× | -0.3% | -0.5% |
| Grape King Bio 1707.TW | Taiwan | $361M | -28% | -7% | 20% | 1.0× | -18.9% | +2.3% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | 10.2× | n/a | n/a |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | 3.4× | 3.0% | +7.0% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | 3.6× | 24.3% | +6.5% |
| Daiken Biomedical 7780.TW | Taiwan | $352M | -24% | n/a | 18% | 3.0× | 0.3% | n/a |
| Zhejiang Xinguang Pharmaceutical 300519.SZ | China | $349M | -11% | +5% | 27% | 5.8× | 5.2% | -1.3% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 4.1× | 20.4% | +12.1% |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 5.2× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | 2.1× | n/a | n/a |
| TCI 8436.TWO | Taiwan | $320M | -24% | -2% | 18% | 1.2× | -13.0% | -3.2% |
| Weihai Baihe Biology Technological 603102.SS | China | $314M | -20% | +18% | 14% | 1.1× | -10.2% | +9.6% |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | 2.0× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | 1.6× | 4.9% | +13.5% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | n/a | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | 3.7× | 1.8% | +4.8% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 1.6× | 14.7% | +15.6% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | 2.5× | 3.6% | -1.3% |